| Literature DB >> 30430081 |
Mei Zhang1,2,3, Jia-Shun Wu1,2,3, Xiao Yang1,2,3, Xin Pang1,2,3, Li Li4, Sha-Sha Wang1,2,3, Jing-Biao Wu1,2,3, Ya-Jie Tang5, Xin-Hua Liang1,2,3, Min Zheng4, Ya-Ling Tang1,2,3.
Abstract
Objective: Cathepsin D (CTSD) is a pivotal orchestrator in the occurrence and development of tumors. Recently, CTSD was detected in salivary adenoid cystic carcinoma (SACC). However, its functional role in perineural invasion (PNI) of SACC remained elusive. We conducted the present study to detect the expression of CTSD in SACC, analyze the correlation between CTSD expression and prognosis of SACC patients and elucidate the role of CTSD in occurrence of PNI in SACC to lay the foundation for further studies.Entities:
Keywords: cathepsin D (CTSD); cytoskeletal organization; invasion frontier; perineural invasion (PNI); salivary adenoid cystic carcinoma (SACC)
Year: 2018 PMID: 30430081 PMCID: PMC6220369 DOI: 10.3389/fonc.2018.00492
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
The expression of Cathepsin D in normal salivary gland and salivary adenoid cystic carcionma.
| Cathepsin D | - | 18 | 28 | 14 | 10 | <0.0001 |
| + | 2 | 31 | 33 | 19 | ||
| ++ | 0 | 15 | 14 | 26 | ||
| +++ | 0 | 7 | 16 | 22 | ||
| 0.0001 0.012 0.023 | ||||||
Normal, normal salivary gland group.
Non-PNI, SACC without PNI group.
PNI (f), far away nerve of SACC with PNI group.
PNI (i), nerve invasion frontier of SACC with PNI group.
Figure 1(A-D) are immunohistochemical staining of CTSD, (×200). (E-H) are immunohistochemical staining of Ki67, (200×). N represents nerve. Normal means normal salivary gland. Non-PNI means non PNI group of SACC. PNI(f) means far away nerve of SACC with PNI group. PNI(i) means nerve invasion frontier of SACC with PNI group.
Correlation between Cathepsin D expression and clinicopathological parameters in salivary adenoid cystic carcinoma.
| 158 | 41 | 47 | 41 | 29 | |||
| Ages (years) | <50 | 73 | 17 | 21 | 19 | 16 | 0.289 |
| ≥50 | 85 | 24 | 26 | 22 | 13 | ||
| Sex | Male | 85 | 26 | 23 | 17 | 19 | 0.645 |
| Female | 73 | 15 | 24 | 24 | 10 | ||
| Complaint (months) | <12 | 83 | 21 | 27 | 19 | 16 | 0.921 |
| ≥12 | 75 | 20 | 20 | 22 | 13 | ||
| Site | Minor salivary gland | 108 | 19 | 38 | 33 | 18 | 0.068 |
| Major salivary gland | 50 | 22 | 9 | 8 | 11 | ||
| Tumor diameter (cm) | ≤1 | 24 | 9 | 7 | 5 | 3 | 0.051 |
| 1~2 | 45 | 14 | 14 | 13 | 4 | ||
| ≥2 | 89 | 18 | 26 | 23 | 22 | ||
| Clinical stage | I+II | 70 | 24 | 23 | 15 | 8 | 0.005 |
| III+IV | 88 | 17 | 24 | 26 | 21 | ||
| Histological subtype | Cribriform | 72 | 21 | 19 | 13 | 19 | 0.044 |
| Tubular | 49 | 16 | 16 | 14 | 3 | ||
| Solid | 37 | 4 | 12 | 14 | 7 | ||
| Involvement of surgical margin | Affect | 48 | 7 | 12 | 23 | 6 | 0.059 |
| free | 110 | 34 | 35 | 18 | 23 | ||
| Local regional recurrence | Positive | 41 | 8 | 10 | 12 | 11 | 0.064 |
| Negative | 117 | 33 | 37 | 29 | 18 | ||
| Distant metastasis | Positive | 46 | 7 | 12 | 9 | 18 | 0.001 |
| Negative | 112 | 34 | 35 | 32 | 11 | ||
Figure 2Kaplan-Meier survival analysis on CTSD negative expression, CTSD weakly positive expression, CTSD moderately positive expression, CTSD strongly positive expression group in the patients with SACC (log-rank test, p < 0.0001).
Multivariate survival analysis for prognostic factors of SACC patients using a Cox regression.
| Clinical stage | 0.796 | 0.280 | 8.100 | 1 | 0.004 | 2.217 | 1.281 | 3.835 |
| Involvement of surgical margin | 0.639 | 0.236 | 7.310 | 1 | 0.007 | 1.894 | 1.192 | 3.009 |
| Local regional recurrence | 0.384 | 0.268 | 2.060 | 1 | 0.151 | 1.469 | 0.869 | 2.482 |
| Distant metastasis | 0.663 | 0.243 | 7.421 | 1 | 0.006 | 1.941 | 1.204 | 3.128 |
| Cathepsin D expression | 0.560 | 0.118 | 22.625 | 1 | 0.000 | 1.750 | 1.390 | 2.204 |
Figure 3Expression of CTSD in SACC tissues and SACC-LM cells. (A) immunofluorescence analysis of CTSD expression in SACC tissue and transfection efficiency of siRNA mediated CTSD knockdown in SACC-LM cells (blank control, negative control, and si-CTSD group), (200×). (B) Western blot analyses of CTSD expression in SACC tissue and transfection efficiency of siRNA mediated CTSD knockdown in SACC-LM cells (blank control, negative control, and si-CTSD group). (C) qRT-PCR analyses of CTSD expression in SACC tissue and transfection efficiency of siRNA mediated CTSD knockdown in SACC-LM cells (blank control, negative control, and si-CTSD group), (***p < 0.001).
Figure 4Effect of CTSD on migration and invasion of SACC-LM cells. (A,B) Scratch wound healing assay showed that CTSD knockdown inhibited the migratory ability of SACC-LM cells, (200×). (C,D) Transwell invasion assay showed that CTSD knockdown inhibited the invasive ability of SACC-LM cells, (200×) (**p < 0.01).
Figure 5Effect of CTSD on PNI of SACC-LM cells. (A,B) In vitro DRG co-culture assay of PNI showed that CTSD knockdown inhibited the ability of PNI of SACC-LM cells, (40×) (**p < 0.01). DRG represents newborn rat dorsal root ganglia (DRG).
Figure 6Effect of CTSD on cytoskeletal organization in SACC-LM cells. siRNA-mediated CTSD silence resulted in morphological changes ranging from a migratory, fibroblastoid phenotype toward epithelial plasticity of SACC-LM, (100×). And FITC-phalloidin staining showed that siRNA-mediated CTSD silence led to a collapse in cytoskeletal organization and reduction in pseudo foot formation, (400×).